A proof-of-concept Phase 2 trial conducted by Mayo Clinic and sponsored by Immunic has shown very early positive results.
We hope that the early evidence gathered from 11 people will lead to a full clinical trial and prove to be promising in treating PSC.
For more information:
Press release by Immunic can be found here.
ClinicalTrials.gov listing can be found here.
Summary: Quoted from 20210218_Immunic_Inc_IMU-838_PSC_IST_Results_Presentation found on this page at immunic-therapeutics.com:
IMU-838 in PSC: Outlook: Feb/18/2021 As an Orally Available DHODH Inhibitor With a Prominent Influence on Th17 Induced Inflammatory Processes, IMU-838 is a Promising Approach for the Treatment of PSC.
The encouraging results regarding biochemical parameters and safety suggest that IMU-838 merits further clinical testing in PSC.
Immunic is in discussions with investigators and leading clinical experts to further evaluate the data set and to explore potential next steps.
Immunic believes that dose optimization would be needed for potential future trials, which would also require assessment of pharmacokinetics in hepatic impaired patients.
All rights reserved © PSC Partners Seeking a Cure